PUK10 BUDGET IMPACT ANALYSIS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN CHINA

Abstract

Prostate cancer (PCa) is one of the most common cancer and one of the leading causes of mortality among males worldwide. This study was to estimate the budget impact of degarelix for the treatment of prostate cancer from Chinese healthcare payer’s perspective. A budget impact model was established to estimate the potential economic impact of adding degarelix to Chinese national reimbursement drug list (NRDL) over a 5-year time horizon (2019-2023). Two scenarios were developed: scenario 1 when degarelix not getting reimbursed by NRDL; scenario 2 when degarelix getting reimbursed by NRDL. The eligible patient population was estimated from China epidemiology statistics. Market share projections were based on market research data. Cost data, including cost of drug, administration and adverse events, were obtained from online sources and KOL survey. The intention-to-treat (ITT) population and a PSA level >20 ng/mL sub-group were analyzed in the model. The incremental aggregate budget impact per year was calculated. Assuming degarelix would be included by NRDL in 2020, the drug cost was estimated to increase by approximately 130 to 650 million RMB from 2020 to 2023 for ITT population. Given that using degarelix would decrease the likelihood of adverse events based on clinical trials, the cost of adverse events would be reduced accordingly; the overall impact would be decreased to 90 ∼ 560 million. For PSA level >20 ng/mL sub-group, the drug cost was estimated to increase by nearly 59 million, 100 million, 190 million, and 300 million RMB in 2020-2023. The overall economic impact would be 42 million, 86 million, 170 million, and 260 million RMB after saving the cost of adverse events. Based on projected market share data, degarelix is likely to have a minimal economic impact on Chinese healthcare system after getting reimbursed by NRDL.